Cutaneous Tumor
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
Topical Anaesthesia in Cutaneous Head and Neck Surgery
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study